ArticleTranslational vision science & technology2014
Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema.
Article in Translational vision science & technology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Implantable ocular therapeutic systems: an insight into their clinical potential in the long-term treatment of ocular diseases.Biofabrication · 2026Review
- External stimuli-responsive drug delivery to the posterior segment of the eye.Drug delivery · 2025Review
- Progress in Ocular Drug Delivery: Challenges and Constraints.Handbook of experimental pharmacology · 2024Article
- Biomaterial Drug Delivery Systems for Prominent Ocular Diseases.Pharmaceutics · 2023Review
- Ocular Delivery of Therapeutic Proteins: A Review.Pharmaceutics · 2023Review
- Usefulness of direct intratumoral administration of doxorubicin hydrochloride with an electro-osmosis-assisted pump.Frontiers in drug delivery · 2023Article
- The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery.Drug delivery · 2022Article
- Fouling in ocular devices: implications for drug delivery, bioactive surface immobilization, and biomaterial design.Drug delivery and translational research · 2021Review
- Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration.Pharmaceutics · 2021Article
- A Wirelessly Controlled Scalable 3D-Printed Microsystem for Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases.Pharmaceutics · 2021Review
- Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema.Pharmaceutics · 2021Article
- Nanoparticle-Hydrogel Composite Drug Delivery System for Potential Ocular Applications.Polymers · 2021Article
- Novel Needle for Intravitreal Drug Delivery: Comparative Study of Needle Tip Aspirates, Injection Stream and Penetration Forces.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- In-Vivo Microsystems: A Review.Sensors (Basel, Switzerland) · 2020Review
- Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases.Eye (London, England) · 2020Review
- A 3D-Printed Modular Microreservoir for Drug Delivery.Micromachines · 2020Article
- The Evolving Treatment of Diabetic Retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices.Frontiers in bioengineering and biotechnology · 2020Review
- Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases.Biomedical microdevices · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo demonstrate the safety and surgical feasibility of the first-in-man ocular implant of a novel Posterior MicroPump Drug Delivery System (PMP) in patients with diabetic macular edema (DME) and to report on the device capabilities for delivering a programmable microdose.
methodsThis was a single center, single arm, open-label, prospective study. Eleven patients with DME and visual acuity equal to or worse than 20/40 were included. The PMP prefilled with ranibizumab was implanted into the subconjunctival space. After implantation, the PMP was wirelessly controlled to deliver a programmed microdose. Comprehensive ophthalmic exams and optical coherence tomography were performed biweekly for 90 days. At the end of the study, the PMP was explanted and the subjects thereafter received standard of care for DME (i.e., laser or intravitreal injections).
resultsAll 11 surgical implantations were without complications and within the skill sets of a retinal surgeon. No serious adverse events occurred during the follow-up period. At no point were visual acuity and central foveal thickness worse than baseline in the implanted eye. The PMP delivered the programmed ranibizumab dosage in seven subjects. The remaining four patients received a lower than target dose, and the treatment was complemented with standard intravitreal injection.
conclusionsThis study demonstrates the first-in-man safety of the Replenish MicroPump implant for a period of 90 days and its capability to deliver a microdose into the vitreous cavity. Further studies to enable longer-term safety and to demonstrate the feasibility of multiple programmable drug delivery are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.